GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Cyclically Adjusted Book per Share

Regulus Therapeutics (Regulus Therapeutics) Cyclically Adjusted Book per Share : $105.58 (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Regulus Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $1.047. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $105.58 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Regulus Therapeutics's average Cyclically Adjusted Book Growth Rate was -19.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-04-29), Regulus Therapeutics's current stock price is $2.52. Regulus Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $105.58. Regulus Therapeutics's Cyclically Adjusted PB Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regulus Therapeutics was 0.03. The lowest was 0.00. And the median was 0.00.


Regulus Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Regulus Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Cyclically Adjusted Book per Share Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -776.78 121.85 130.31 105.58

Regulus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.31 126.52 122.58 114.77 105.58

Competitive Comparison of Regulus Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Regulus Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Cyclically Adjusted PB Ratio falls into.



Regulus Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regulus Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.047/129.4194*129.4194
=1.047

Current CPI (Dec. 2023) = 129.4194.

Regulus Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 255.487 99.695 331.663
201406 227.043 100.560 292.203
201409 204.647 100.428 263.725
201412 323.667 99.070 422.821
201503 347.088 99.621 450.908
201506 308.837 100.684 396.980
201509 288.549 100.392 371.982
201512 282.696 99.792 366.625
201603 243.819 100.470 314.072
201606 201.513 101.688 256.467
201609 164.811 101.861 209.400
201612 127.143 101.863 161.539
201703 87.387 102.862 109.949
201706 45.117 103.349 56.498
201709 56.081 104.136 69.697
201712 40.652 104.011 50.583
201803 26.315 105.290 32.346
201806 11.989 106.317 14.594
201809 1.803 106.507 2.191
201812 -6.639 105.998 -8.106
201903 -5.610 107.251 -6.770
201906 2.278 108.070 2.728
201909 -0.068 108.329 -0.081
201912 9.521 108.420 11.365
202003 5.396 108.902 6.413
202006 2.389 108.767 2.843
202009 1.979 109.815 2.332
202012 3.859 109.897 4.545
202103 3.630 111.754 4.204
202106 4.231 114.631 4.777
202109 3.333 115.734 3.727
202112 3.765 117.630 4.142
202203 3.373 121.301 3.599
202206 2.895 125.017 2.997
202209 2.355 125.227 2.434
202212 1.977 125.222 2.043
202303 1.577 127.348 1.603
202306 1.745 128.729 1.754
202309 1.397 129.860 1.392
202312 1.047 129.419 1.047

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Regulus Therapeutics  (NAS:RGLS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regulus Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.52/105.58
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regulus Therapeutics was 0.03. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Regulus Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (Regulus Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Executives
Crispina Calsada officer: Chief Financial Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Christopher Ray Aker officer: Sr. VP & General Counsel C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Joseph P Hagan officer: Chief Operating Officer 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Preston Klassen officer: President & Head of R & D 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Denis Drygin officer: Chief Scientific Officer 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang director 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner

Regulus Therapeutics (Regulus Therapeutics) Headlines